Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: mesaone who wrote (88)	3/5/1999 9:04:00 PM
From: Stephen How	Read Replies (2) \| Respond to of 10293

mesaone, I spent an inordinate time researching BTIM. As you know, I studied current papers on hydroxyethyl starches (HES) and plasma expanders, their coagulation problems. I came up with the same skeptical conclusions that the experts arrived at -- that Hextend® = Hespan® + electrolytes, and will not command a premium in the (small) marketplace. I remember the Abbott conference call said that Hextend will address a market between $40M and $400M. I think that everyone knows the market is very close to $40M and that Abbott was just trying to save face over the embarassing matter. The BTIM longs have done an excellent job in making their shares non-borrowable. I also sincerely think you've help drive the price back up -- congrats. I want to short BTIM following the FDA approval spike. I'm just worried that I won't be able to get shares. I'll look into getting shares at my various brokerages. I know that the long crowd sees share prices in the hundreds in the next few years. I still think the stock will head to $0. Either way, it'll be fun, Steve angelfire.com (I link to your page, why don't you link to mine? :>)